Qlaris Bio announces development of fixed-dose combination therapy with QLS-111 and latanoprost for the treatment of glaucoma

Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care DEDHAM, Mass. — June 11, 2025 — Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and […]